Breaking News Instant updates and real-time market news.

GHDX

Genomic Health

$70.84

1.65 (2.38%)

, LH

LabCorp

$169.54

-2.46 (-1.43%)

05:09
09/25/18
09/25
05:09
09/25/18
05:09

Piper sees early winners from annual list of new codes from CMS

The Centers for Medicare & Medicaid Services published its annual list of new codes ahead of the final rate determination including 99 codes, Piper Jaffray analyst William Quirk tells investors in a research note. He says Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA) and Quest Diagnostics (DGX) look like early winners in the 2019 Preliminary Clinical Laboratory Fee Schedule Fee Schedule determinations, with an incrementally positive competitive move for CareDx (CDNA). The analyst notes that Genomic Health received increased reimbursement for a couple tests and CareDx competitor TAI Diagnostics ends up with a likely longer pathway to reimbursement.

GHDX

Genomic Health

$70.84

1.65 (2.38%)

LH

LabCorp

$169.54

-2.46 (-1.43%)

MYGN

Myriad Genetics

$46.91

0.64 (1.38%)

NTRA

Natera

$23.83

-0.35 (-1.45%)

DGX

Quest Diagnostics

$107.61

-0.01 (-0.01%)

  • 26

    Sep

  • 06

    Nov

  • 27

    Nov

GHDX Genomic Health
$70.84

1.65 (2.38%)

06/13/18
LTCO
06/13/18
DOWNGRADE
LTCO
Neutral
Genomic Health downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter downgraded Genomic Health to Neutral due to valuation with the shares above his previous price target of $49.50.
06/04/18
ADAM
06/04/18
NO CHANGE
Target $45
ADAM
Buy
Genomic Health price target raised to $45 from $41 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Genomic Health to $45 from $41 following the release of its historic TAILORx trial, which is the largest breast cancer treatment trial ever conducted. The data showed some incremental boost to Onctoype Dx volumes and the trial established that chemo may provide life-saving benefit to 30% of patients. Massaro reiterated his Buy rating on Genomic Health shares.
01/10/18
COWN
01/10/18
NO CHANGE
COWN
Market Perform
NICE guidance on Genomic Health test 'somewhat surprising,' says Cowen
Cowen analyst Doug Schenkel noted that the U.K.'s National Institute for Health and Care Excellence, or NICE, reversed a previous decision with new draft guidance that does not recommend Genomic Health's Oncotype test in guiding chemotherapy decisions for breast cancer patients. He finds this "somewhat surprising" given the test's inclusion in other international guidelines and think this could lead to some slight tempering of expectations if finalized. Schenkel has a Market Perform rating on Genomic Health shares.
12/20/17
WBLR
12/20/17
DOWNGRADE
WBLR
Market Perform
Genomic Health downgraded to Market Perform from Outperform at William Blair
William Blair analyst Amanda Murphy downgraded Genomic Health to Market Perform citing valuation with the shares rallying recently on reports of a potential sale.
LH LabCorp
$169.54

-2.46 (-1.43%)

06/27/18
06/27/18
DOWNGRADE

Hold
Deutsche Bank downgrades Quest, LabCorp to Hold with catalysts 'exhausted'
As previously reported, Deutsche Bank analyst Dan Leonard downgraded Quest Diagnostics (DGX) and LabCorp (LH), both to Hold from Buy, stating that he previously believed that hospital labs, which could be more impaired by Medicare reimbursement cuts, would be willing sellers, but the slower than expected pace of deals has made him question this assumption. He continues to see durable organic growth for Quest's and LabCorp's diagnostics businesses, but he now wonders if some headwinds had abated in the way he'd previously assumed, Leonard added.
06/27/18
DBAB
06/27/18
DOWNGRADE
DBAB
Hold
LabCorp downgraded to Hold from Buy at Deutsche Bank
06/25/18
LEHM
06/25/18
UPGRADE
Target $130
LEHM
Overweight
Quest Diagnostics upgraded to Overweight from Equal Weight at Barclays
As previously reported, Barclays analyst Jack Meehan upgraded Quest Diagnostics (DGX) to Overweight from Equal Weight and raised his price target to $130 from $120, telling investors in a research note that Quest has a "very favorable" risk-reward profile and current levels. Meehan contends that it "could be a big deal" that UnitedHealth (UNH) will share savings with preferred labs as volume shifts from high-cost settings, a first for the lab industry, and that his primary care physician survey indicates that both Quest and LabCorb (LH) should gain share as payor networks open. Additionally, Meehan says the "pieces are in place" for Quest to more meaningfully leverage its diagnostic data asset with customers. Commenting further on Top Pick LabCorp, Meehan believes industry themes that bode well for Quest also bode well for LabCorp.
06/08/18
WBLR
06/08/18
UPGRADE
WBLR
Outperform
William Blair upgrades Quest Diagnostics to Outperform on secular tailwinds
William Blair analyst Amanda Murphy upgraded Quest Diagnostics (DGX) to Outperform from Market Perform citing the recent UnitedHealthcare (UNH) contract change and positive secular trends for larger labs. The analyst believes both LabCorp (LH) and Quest should benefit from secular tailwinds. We are in the early innings of a cycle of lab market share shift from hospital labs to independent labs, Murphy tells investors in a research note. She finds it hard to argue that the new it is hard to argue that the new UnitedHealthcare contract is not good for Quest.
MYGN Myriad Genetics
$46.91

0.64 (1.38%)

09/05/18
LEHM
09/05/18
UPGRADE
Target $90
LEHM
Equal Weight
Barclays upgrades PerkinElmer to Equal Weight with $90 target
Barclays analyst Jack Meehan upgraded PerkinElmer (PKI) to Equal Weight from Underweight and raised his price target for the shares to $90 from $79. The analyst is more positive on PerkinElmer's near-term growth prospects in Diagnostics due to its recent investments. Combined with margin expansion and capital deployment, he thinks PerkinElmer is better positioned to drive low-to-mid teens earnings growth. Meehan this morning also downgraded Hologic (HOLX) to Equal Weight and Myriad Genetics (MYGN) to Underweight.
09/05/18
09/05/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tyson Foods (TSN) downgraded to Hold from Buy at Argus with analyst John Staszak saying the rating change reflects his heightened concerns over the company's increased expenses from higher freight and labor costs. 2. Robert Half (RHI) downgraded to Sell from Neutral at Goldman Sachs with analyst George Tong saying he views the company's valuation as full relative to its growth outlook. 3. CSX (CSX) and Canadian National (CNI) were downgraded to Market Perform from Outperform at BMO Capital. 4. Myriad Genetics (MYGN) downgraded to Underweight from Equal Weight at Barclays with analyst Jack Meehan saying with the stock near an 18-year high, several company risks create an unfavorable risk/reward profile. 5. Vail Resorts (MTN) downgraded to Neutral from Outperform at Macquarie with analyst Matthew Brooks citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/05/18
09/05/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. DEUTSCHE RESUMES CATERPILLAR WITH A BUY: Deutsche Bank analyst Chad Dillard resumed coverage of Caterpillar (CAT) with a Buy rating and $177 price target. Since late cycle concerns took hold in April, the Machinery sector has underperformed the S&P 500 by 15% and is approaching valuation lows last seen during the 2015 energy and 2008 global financial crises, Dillard noted. MORGAN STANLEY UPGRADES ANTHEM TO OVERWEIGHT: Morgan Stanley analyst Zack Sopcak upgraded Anthem (ANTM) to Overweight from Equal Weight, contending that the disruption in the pharmacy benefits management landscape via M&A and government-led drug pricing reform positions Anthem for underappreciated share gain and accelerated profit growth. He raised his price target for Anthem shares to $368 from $273. BARCLAYS CUTS MYRIAD TO UNDERWEIGHT: Barclays analyst Jack Meehan downgraded Myriad Genetics (MYGN) to Underweight from Equal Weight and cut his price target for the shares to $30 from $38. With the stock near an 18-year high, several company risks create an unfavorable risk/reward profile, Meehan said. He sees "several risks" around the GeneSight Randomized Control Trial, which he thinks present risks for payor coverage. Further, the analyst is cautious around the sustainability of hereditary cancer testing pricing longer term. CITI STARTS UNIVERSAL DISPLAY WITH A BUY: Citi analyst Atif Malik started Universal Display (OLED) with a Buy rating and $153 price target. The analyst said that despite a 52% recovery in the stock price in the last two months after a sharp correction in 2018 on weak iPhone X demand, he sees "steady improvement" in OLED fundamentals and stock price through 2019. He believes Samsung Galaxy Note and two of the three upcoming iPhone models using OLED is a "strong indicator that adoption is headed in the right direction." UBS CUTS GE PRICE TARGET TO $13: UBS analyst Steven Winoker lowered his price target for shares of General Electric (GE) to $13 from $16 and kept a Neutral rating on the name. There should be no argument that GE Power is struggling, Winoker said. The analyst points out that GE Power sales fell 26% in Q2 as GE's overall revenue dropped 18%. While cost cuts in the segment remain a focus, end markets are "far from cooperative with regard to pricing, demand and competition," Winoker added. The analyst sees an "even harder road ahead for GE Power."
09/11/18
LEHM
09/11/18
NO CHANGE
Target $25
LEHM
Underweight
Myriad Genetics price target lowered to $25 from $30 at Barclays
Barclays analyst Jack Meehan lowered his price target for Myriad Genetics to $25 and keeps a Underweight rating on the name. The analyst has new concerns with the Impact study for Myriad's GeneSight after performing additional diligence. He notes that Myriad is submitting the study to Medicare for expanded coverage for primary care physicians. Meehan says that if the Centers for Medicare & Medicaid Services shares some of the same concerns, it increases the chances of a more limited coverage outcome for Myriad.
NTRA Natera
$23.83

-0.35 (-1.45%)

08/16/18
ADAM
08/16/18
NO CHANGE
Target $29
ADAM
Buy
Natera price target raised to $29 from $25 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Natera to $29 from $25 noting that its Q2 volumes beat expectations. The beat was driven by continued execution of its industry-leading Panorama NIPT test, but it is also signing impressive deals and expanding the breadth of its cancer offerings, said Massaro, who reiterated his Buy rating on Natera shares.
08/09/18
CHLM
08/09/18
NO CHANGE
Target $30
CHLM
Buy
Natera price target raised to $30 from $23 at Craig-Hallum
Craig-Hallum analyst Alexander Nowak raised his price target to $30 from $23 after the company reported another "solid" quarter with strong volume growth of 29%, a continuation of the 36% growth from Q1 and evidence that Q1 was not a one-quarter phenomenon. The analyst reiterates a Buy rating on the shares.
08/09/18
PIPR
08/09/18
NO CHANGE
Target $27
PIPR
Overweight
Natera price target raised to $27 from $21 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Natera to $27 saying he has a higher level of confidence in its ability to transform into a platform company following the Q2 results. Natera is further differentiating its core NIPT offering with the Fetal Fraction risk biomarker which can extend its market leadership, Quirk tells investors in a post-earnings research note. Further, the company has expanded oncology partnerships faster than expected and will retain distribution for transplant, he adds. Quirk keeps an Overweight rating on Natera.
07/20/18
CHLM
07/20/18
NO CHANGE
Target $23
CHLM
Buy
Buy Natera shares on any potential post-Aetna weakness, says Craig-Hallum
Craig-Hallum analyst Alexander Nowak says news that Aetna (AET) updated its prenatal testing medical policy, deciding not to cover average risk testing, is "disappointing" given ACOG's recent stance change on average risk, telling investors he believes Aetna's decision adds risk to UnitedHealth's (UNH) upcoming review, which is scheduled for early 2019. Nowak says he continues to like the Natera (NTRA) story and long-term potential and would be buying shares on any possible post-Aetna weakness.
DGX Quest Diagnostics
$107.61

-0.01 (-0.01%)

07/25/18
BARD
07/25/18
NO CHANGE
Target $120
BARD
Outperform
Quest Diagnostics selloff understandable, but overdone, says Baird
Baird analyst Eric Coldwell said the selloff in Quest Diagnostics following its Q2 miss is understandable, but perhaps overdone. He believes the company's headwinds remain manageable and he doesn't think much has changed to the story with the exception of maybe a roughly 20 basis point revenue growth reduction. Coldwell reiterated his Outperform rating and $120 price target on Quest Diagnostics shares.
07/25/18
ADAM
07/25/18
NO CHANGE
Target $118
ADAM
Buy
Quest Diagnostics decline fair, but big picture intact, says Canaccord
Canaccord analyst Mark Massaro said the decline in Quest Diagnostics shares following its Q2 miss and lowered top-line guidance was fair. Despite the miss, the analyst believes the story remains intact as he believes the company will take market share, is poised to win more business, and he expects the pace of M&A to increase. Massaro reiterated his Buy rating and lowered his price target to $118 from $122 on Quest Diagnostics shares.
07/10/18
07/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CarMax (KMX) upgraded two notches to Overweight from Underweight at Morgan Stanley with analyst Armintas Sinkevicius saying longer term, he is constructive on dealers, citing a belief that tech disruption could accelerate consolidation and set up a transition toward "megafleet managers." 2. Cummins (CMI) upgraded to Buy from Hold at Stifel with analyst Michael Baudendistel saying shares of truck equipment companies have been under pressure primarily on concerns that the cycle is at a peak. 3. Wynn Resorts (WYNN) upgraded to Buy from Hold at Stifel with analyst Steven Wieczynski saying he believes the pullback in the stock recently has created a compelling opportunity. 4. KB Home (KBH) upgraded to Positive from Neutral at Susquehanna with analyst Jack Micenko citing a "clear and visible path" to further gross margin expansion and re-acceleration in community count and order growth well into 2019 for the upgrade, adding that underlying housing trends are strong in many of the markets in which the company currently operates despite "cautious" macro sentiment. 5. Quest Diagnostics (DGX) upgraded to Outperform from In Line at Evercore ISI with analyst Ross Muken saying the company will likely be the beneficiary of improved volumes, stable pricing, heightened M&A, and fund flows amid the heightened volatility within the Rx supply chain. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/24/18
FBCO
09/24/18
NO CHANGE
Target $128
FBCO
Outperform
Quest Diagnostics price target raised to $128 from $121 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Quest Diagnostics to $128 from $121 after meeting with CEO Steve Rusckowski and VP of Investor Relations Shawn Bevec. The analyst notes that management sees the clinical lab industry going through a period of disruptive change that should play to the strengths of national laboratory companies, such as Quest, at the expense of small regional labs and hospital outreach programs. Rice reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

FLWS

1-800-Flowers.com

$17.82

-0.18 (-1.00%)

08:50
05/24/19
05/24
08:50
05/24/19
08:50
Upgrade
1-800-Flowers.com rating change  »

1-800-Flowers.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 25

    Sep

08:50
05/24/19
05/24
08:50
05/24/19
08:50
General news
Treasury Action: yields dipped in the wake of the durables report »

Treasury Action: yields…

HIBB

Hibbett Sports

$19.84

-0.18 (-0.90%)

08:46
05/24/19
05/24
08:46
05/24/19
08:46
Recommendations
Hibbett Sports analyst commentary  »

Hibbett Sports'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

DVAX

Dynavax

$6.36

(0.00%)

08:46
05/24/19
05/24
08:46
05/24/19
08:46
Recommendations
Dynavax analyst commentary at RBC Capital »

Dynavax price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 05

    Jun

DFRG

Del Frisco's

$6.79

-0.1 (-1.45%)

, LABD

Daily S&P Biotech Bear 3x Shares

$23.31

0.66 (2.91%)

08:45
05/24/19
05/24
08:45
05/24/19
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

DFRG

Del Frisco's

$6.79

-0.1 (-1.45%)

LABD

Daily S&P Biotech Bear 3x Shares

$23.31

0.66 (2.91%)

FANG

Diamondback Energy

$103.78

-4.9 (-4.51%)

EWZ

MSCI Brazil Index

$39.10

-0.3 (-0.76%)

PEI

Pennsylvania REIT

$6.66

-0.04 (-0.60%)

WPG

Washington Prime

$4.47

0.015 (0.34%)

IWM

iShares Trust Russell 2000 Index Fund

$149.40

-3.17 (-2.08%)

BILI

Bilibili

$14.32

-0.37 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 30

    May

  • 04

    Jun

  • 06

    Jun

  • 06

    Jun

  • 26

    Jun

  • 13

    Nov

NPTN

NeoPhotonics

$3.88

-0.085 (-2.14%)

08:43
05/24/19
05/24
08:43
05/24/19
08:43
Recommendations
NeoPhotonics analyst commentary  »

NeoPhotonics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 04

    Jun

ZYME

Zymeworks

$17.65

0.02 (0.11%)

08:42
05/24/19
05/24
08:42
05/24/19
08:42
Conference/Events
Zymeworks to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SPLK

Splunk

$128.68

-7.12 (-5.24%)

08:41
05/24/19
05/24
08:41
05/24/19
08:41
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

  • 09

    Jul

PDVW

pdvWireless

$44.25

1.25 (2.91%)

08:40
05/24/19
05/24
08:40
05/24/19
08:40
Recommendations
pdvWireless analyst commentary  »

pdvWireless price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 13

    Jun

08:40
05/24/19
05/24
08:40
05/24/19
08:40
General news
FX Action: The dollar »

FX Action: The dollar…

08:40
05/24/19
05/24
08:40
05/24/19
08:40
General news
U.S. durable goods orders fell 2.1% in April »

U.S. durable goods orders…

08:40
05/24/19
05/24
08:40
05/24/19
08:40
General news
U.S. equities are modestly firmer »

U.S. equities are…

BCRX

BioCryst

$3.54

0.09 (2.61%)

08:37
05/24/19
05/24
08:37
05/24/19
08:37
Downgrade
BioCryst rating change  »

BioCryst downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

PLUS

ePlus

$72.62

-13.88 (-16.05%)

08:36
05/24/19
05/24
08:36
05/24/19
08:36
Hot Stocks
ePlus announces 500,000 share stock repurchase program »

ePlus announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASH

Ashland

$72.19

-0.435 (-0.60%)

08:35
05/24/19
05/24
08:35
05/24/19
08:35
Recommendations
Ashland analyst commentary  »

Ashland shares have 30%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLMN

Bloomin' Brands

$18.22

-1.98 (-9.80%)

08:33
05/24/19
05/24
08:33
05/24/19
08:33
Upgrade
Bloomin' Brands rating change  »

Guggenheim upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CETX

Cemtrex

$0.25

0.0158 (6.89%)

08:33
05/24/19
05/24
08:33
05/24/19
08:33
Hot Stocks
Cemtrex announces six-for-one reverse stock split to regain NASDAQ compliance »

Cemtrex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIBB

Hibbett Sports

$19.84

-0.18 (-0.90%)

08:31
05/24/19
05/24
08:31
05/24/19
08:31
Hot Stocks
Hibbett Sports appoints Anthony Crudele as independent chairman »

Hibbett Sports announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

BTU

Peabody Energy

$24.45

-0.855 (-3.38%)

08:30
05/24/19
05/24
08:30
05/24/19
08:30
Hot Stocks
Peabody Energy says proceeding with ventilation of North Goonyella Mine »

Peabody announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNR

China Metro-Rural

$5.70

-0.2 (-3.39%)

, LK

Luckin Coffee

$15.88

0.88 (5.87%)

08:30
05/24/19
05/24
08:30
05/24/19
08:30
Options
Five new option listings and four option delistings on May 24th »

New option listings for…

CNR

China Metro-Rural

$5.70

-0.2 (-3.39%)

LK

Luckin Coffee

$15.88

0.88 (5.87%)

ROAN

Roan Resources

$2.53

-0.32 (-11.23%)

EPE

EP Energy

$0.16

(0.00%)

FRSH

Papa Murphy's

$6.45

(0.00%)

NAVG

Navigators

$69.97

(0.00%)

NCS

NCI Building

$5.70

-0.2 (-3.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$165.84

-2.46 (-1.46%)

08:28
05/24/19
05/24
08:28
05/24/19
08:28
Recommendations
3M analyst commentary  »

3M likely to further…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

HIBB

Hibbett Sports

$19.84

-0.18 (-0.90%)

08:27
05/24/19
05/24
08:27
05/24/19
08:27
Hot Stocks
Hibbett Sports up 14.5% after Q1 results beat estimates, FY20 guidance raised »

In pre-market trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

VALE

Vale

$11.78

0.03 (0.26%)

08:27
05/24/19
05/24
08:27
05/24/19
08:27
Upgrade
Vale rating change  »

Vale upgraded to Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTU

Intuit

$241.30

-6.22 (-2.51%)

08:24
05/24/19
05/24
08:24
05/24/19
08:24
Recommendations
Intuit analyst commentary  »

Intuit price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPN

Global Payments

$147.97

-2.64 (-1.75%)

, TSS

TSYS

$99.61

-1.62 (-1.60%)

08:22
05/24/19
05/24
08:22
05/24/19
08:22
Recommendations
Global Payments, TSYS, ACI Worldwide, Bottomline Technologies, Jack Henry, USA Technologies, Q2 Holdings, Fiserv, First Data, FIS, Worldpay analyst commentary at Stephens »

Global Payments, TSYS…

GPN

Global Payments

$147.97

-2.64 (-1.75%)

TSS

TSYS

$99.61

-1.62 (-1.60%)

ACIW

ACI Worldwide

$31.61

-0.43 (-1.34%)

EPAY

Bottomline Technologies

$44.53

-0.53 (-1.18%)

JKHY

Jack Henry

$132.23

-3.43 (-2.53%)

USAT

USA Technologies

$7.22

0.05 (0.70%)

QTWO

Q2 Holdings

$72.44

-1.98 (-2.66%)

FISV

Fiserv

$87.23

-2.4 (-2.68%)

FDC

First Data

$25.88

-0.75 (-2.82%)

FIS

FIS

$120.45

-0.59 (-0.49%)

WP

Worldpay

$121.97

-0.48 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 03

    Jun

  • 05

    Jun

  • 11

    Jun

  • 11

    Jun

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.